Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-109 Combined With Chemotherapy as First-Line Treatment for NSCLC Carrying EGFR Exon 20 Insertion Mutations
NCT06514027Phase 2Recruiting
- Sponsor
- BeBetter Med
- Start
- Aug 2024
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of BEBT-109 in non-small cell lung cancer (NSCLC), sponsored by BeBetter Med. Started Aug 2024; status: recruiting.
02
Drugs
BEBT-109
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06514027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514027.